A method for the diagnosis and differentiation of acute myocardial infarction (AMI) patients by Nourin protein and its novel autophagy-related Nourin gene-based RNA molecular network, comprising the steps of:
- a) identifying a novel autophagy-related Nourin gene-based RNA network;
- b) retrieving from the Nourin gene-based RNA network of step (a), Nourin gene-based RNA biomarkers, relevant to AMI and related to a Nourin peptide sequence, comprising:
- i) ferritin heavy polypeptide 17 (FTHL-17) gene for Nourin mRNA related to autophagy and cardiac ischemia,
- ii) homo sapiens micro RNA-137 (hsa-miRNA-137), an autophagy-related gene for cardiac ischemia as a regulatory gene on FTHL-17, and
- iii) long non-coding intergenic RNA (lnc-RNA-CTB89H12.4), an autophagy-related gene for cardiac ischemia and regulates hsa-miRNA-137;
- c) measuring and analyzing the Nourin gene-based RNA biomarkers from step (b) and Nourin protein levels in a sample, wherein the sample is fresh or frozen serum or plasma from a subject;
- d) using the analysis of the sample in step (c) for the diagnosis of an AMI patient at the presentation to hospital emergency department with symptoms of chest pain;
- e) differentiating the subject from whom the sample is obtained in step (c) into an AMI patient or a non-cardiac patient or a healthy control volunteer using the analysis of step (c) at the presentation to hospital emergency department with symptoms of chest pain,
- wherein, the Nourin peptide sequence in step (b) is formyl substituted-MIINHNLAAINSHR as set forth in SEQ ID NO:15 that is the N-terminus portion of the Nourin peptide sequence,
- wherein, the Nourin gene-based RNA biomarkers comprising, lncRNA-CTB89H12.4, hsa-miRNA-137, and FTHL-17 mRNA show differential expression as measured in step (c) in pathological cardiomyocytes as an autophagy-related RNA panel linked to each other and to cardiovascular ischemia to specifically identify ischemic cardiac events in AMI,
- wherein the Nourin protein levels as measured in step (c) show differential expression in pathological cardiomyocytes linked to the Nourin gene-based RNA biomarkers comprising, lncRNA-CTB89H12.4, hsa-miRNA-137, and FTHL-17 mRNA useful to differentiate the sample obtained from an AMI patient from the sample obtained from a non-cardiac patient or a healthy control volunteer at the presentation to hospital emergency department with symptoms of chest pain,
- wherein an up-regulation of the Nourin gene-based RNA biomarkers, hsa-miRNA-137, and FTHL-17 mRNA, with a down-regulation of the Nourin gene-based RNA biomarker, lncRNA-CTB89H12.4, and an up-regulation of Nourin protein levels provide the diagnosis of a sample as from an AMI patient, and
- wherein the differentiation is based on the absence of elevated levels of Nourin gene-based RNA molecular network consisting of the Nourin gene-based RNA biomarkers and Nourin protein level that rules out and differentiates AMI patients from non-cardiac patients and healthy control volunteers at the presentation to hospital emergency department with chest pains.